Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
01 November 2021Website:
http://www.lianbio.comNext earnings report:
N/ALast dividends:
15 March 2024Next dividends:
N/APrice
regular market | Wed, 03 Jul 2024 13:30:00 GMTAnalysts recommendations
Institutional Ownership
LIAN Latest News
LianBio (NASDAQ: LIAN ) stock is moving on Friday and this is likely tied to the company's voluntary delisting of its shares from the Nasdaq Exchange. LianBio announced late last month plans to voluntarily delist shares of LIAN stock.
LianBio Sponsored ADR (LIAN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
LianBio has entered into a major deal with Bristol Myers Squibb. Bristol Myers will pay $350 million for the rights to develop and commercialize LianBio's mavacamten treatment in select Asian countries and territories.
Shares of LianBio (NASDAQ: LIAN ) — which focuses on “developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries” — are soaring on Tuesday. Earlier this morning, the company announced a key agreement with Bristol-Myers Squibb (NYSE: BMY ) regarding exclusive rights to a cardiovascular therapeutic.
LianBio entered into a deal to give Bristol Myers Squibb exclusive rights for mavacemten in China and other Asian markets. The small drugmaker will receive $350 million.
SHANGHAI, China and PRINCETON, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that members of the management team will participate in the following upcoming investor conferences:
What type of business is LianBio?
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
What sector is LianBio in?
LianBio is in the Healthcare sector
What industry is LianBio in?
LianBio is in the Biotechnology industry
What country is LianBio from?
LianBio is headquartered in United States
When did LianBio go public?
LianBio initial public offering (IPO) was on 01 November 2021
What is LianBio website?
https://www.lianbio.com
Is LianBio in the S&P 500?
No, LianBio is not included in the S&P 500 index
Is LianBio in the NASDAQ 100?
No, LianBio is not included in the NASDAQ 100 index
Is LianBio in the Dow Jones?
No, LianBio is not included in the Dow Jones index
When does LianBio report earnings?
Next earnings report date is not announced yet